These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 14602969)

  • 1. Parkinson's disease.
    Constantino AE; Honig LS
    Sci Aging Knowledge Environ; 2001 Nov; 2001(7):dn4. PubMed ID: 14602969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
    Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
    Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatments of Parkinson disease: circa 2003.
    Shults CW
    Arch Neurol; 2003 Dec; 60(12):1680-4. PubMed ID: 14676041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease.
    Béné R; Antić S; Budisić M; Lisak M; Trkanjec Z; Demarin V; Podobnik-Sarkanji S
    Acta Clin Croat; 2009 Sep; 48(3):377-80. PubMed ID: 20055267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphological alterations of the synapses in the locus coeruleus in Parkinson's disease.
    Baloyannis SJ; Costa V; Baloyannis IS
    J Neurol Sci; 2006 Oct; 248(1-2):35-41. PubMed ID: 16753180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's disease: clinical aspects.
    Klockgether T
    Cell Tissue Res; 2004 Oct; 318(1):115-20. PubMed ID: 15365814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synucleins and their relationship to Parkinson's disease.
    von Bohlen Und Halbach O
    Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Frequency of the IVS4+66A-G polymorphism in the alpha-synuclein gene in patients with Parkinson's disease in north-western Mexico].
    Ramírez-Jirano LJ; Ruiz-Sandoval JL; Jiménez-Gil FJ; Ramírez-Vega J; Vargas-Frutos E; Gallegos-Arreola MP
    Rev Neurol; 2007 Jan 1-15; 44(1):15-7. PubMed ID: 17199224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intralaminar nuclei of the thalamus in Lewy body diseases.
    Brooks D; Halliday GM
    Brain Res Bull; 2009 Feb; 78(2-3):97-104. PubMed ID: 18804518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores.
    Atasoy HT; Nuyan O; Tunc T; Yorubulut M; Unal AE; Inan LE
    Neurol India; 2004 Sep; 52(3):332-7. PubMed ID: 15472421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of Parkinson's disease.
    Lew M
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):155S-160S. PubMed ID: 18041935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An autopsy case of senile dementia with pathological features of Parkinson's disease].
    Oshima K; Tsuchiya K; Iritani S; Niizato K; Akiyama H; Ikeda K; Arai H
    No To Shinkei; 2004 Jul; 56(7):603-6. PubMed ID: 15379289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
    Chu Y; Kordower JH
    Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localization of CKII beta subunits in Lewy bodies of Parkinson's disease.
    Ryu MY; Kim DW; Arima K; Mouradian MM; Kim SU; Lee G
    J Neurol Sci; 2008 Mar; 266(1-2):9-12. PubMed ID: 17884098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Premotor diagnosis of Parkinson's disease].
    Morales-Briceño H; Cervantes-Arriaga A; Rodríguez-Violante M
    Gac Med Mex; 2011; 147(1):22-32. PubMed ID: 21412393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.